Skip to content
Screener

BioMarin Pharmaceuticals BMRN Unrealized Losses on Investments (Before Tax)

Unrealized Losses on Investments (Before Tax) at other companies

BridgeBio Pharma logo
BridgeBio PharmaBBIO
$6K—
Denali Therapeutics Inc. logo
Denali Therapeutics Inc.DNLI
$801K+1,028%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
——
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
——
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
——

Other financials

Income statement

See full
Revenue$989.7M+19.9%
Gross profit$786.9M+16.5%
Operating income$110.9M-59.9%
Net income$44.8M-81.4%
EPS (diluted)$0.23-81.3%

Balance sheet

See full
Cash & equivalents$874.0M-28.0%
Total debt$4.2B+598%
Total equity$6.3B+4.9%
Total assets$11.7B+57.2%

Cash flow

See full
Operating cash flow$168.1M-9.3%
CapEx$28.8M+68.5%
Free cash flow$139.3M-17.2%

Valuation

See full
Market cap$13.33B+21.1%
Enterprise value$16.65B+60.1%
P/E37×-39.9×
P/S3.9×+0.3×

Profitability

See full
Gross margin76.1%-3.4pp
Operating margin19.9%+7.2pp
Net margin16.8%+5.1pp
FCF margin21.7%-1.0pp

Returns & leverage

See full
Return on equity9.1%+2.8pp
Debt / equity0.7×+0.6×
Current ratio2.4×-3.2×

Where this comes from

Reported directly by BioMarin Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.

The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:14 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001048477-26-000016
Line itemAmortized CostGross Unrealized GainsGross Unrealized LossesAggregate Fair ValueCash and Cash Equivalents
Level 1:
Cash$527,517——$527,517$527,517
Level 2:
Money market instruments346,488——346,488346,488
Total$874,005——$874,005$874,005

Item 1. Financial Statements

FAQ

What is BioMarin Pharmaceuticals's unrealized losses on investments (before tax)?
BioMarin Pharmaceuticals (BMRN) reported unrealized losses on investments (before tax) of $0 in Q2 2026.
How has BioMarin Pharmaceuticals's unrealized losses on investments (before tax) changed year-over-year?
BioMarin Pharmaceuticals's unrealized losses on investments (before tax) decreased by 100.0% year-over-year, from $106K to $0.
What is the long-term trend for BioMarin Pharmaceuticals's unrealized losses on investments (before tax)?
Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's unrealized losses on investments (before tax) has grown at a -6.2% compound annual growth rate (CAGR), from $11K to $8K.
What does unrealized losses on investments (before tax) mean?
The total unrealized losses on investments, typically related to available-for-sale securities, before considering tax effects.

Ask your AI about BioMarin Pharmaceuticals's unrealized losses on investments (before tax).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude